India’s cancer-drug pricing debate has intensified after an analysis found trade mark-ups of up to 700% on some anti-cancer medicines, despite the National Pharmaceutical Pricing Authority’s (NPPA) 2019 intervention to restrict margins. The findings suggest that one-time price reductions did not prevent some medicine prices from rising again over the following years.
The issue has gained fresh attention as the government introduces a new trade-margin rationalisation exercise covering 137 non-scheduled cancer drugs, with revised prices scheduled to take effect on November 9, 2026. The latest intervention is intended to reduce excessive distribution mark-ups, but experts and patient advocates warn that controlling trade margins does not necessarily make every expensive cancer medicine affordable.
Key Takeaways
- Some cancer medicines in India have recorded trade mark-ups of up to 700%, according to NPPA data discussed in October 2026.
- The NPPA’s February 2019 intervention imposed a 30% trade-margin cap on 42 non-scheduled cancer drugs.
- An analysis found that many medicines covered by the earlier exercise again had mark-ups exceeding 43% by 2026.
- The price of a Pemetrexed brand fell from ₹7,000 to ₹800 in 2019, but its price later increased before another reduction.
- The government has now extended trade-margin rationalisation to 137 non-scheduled anti-cancer drugs.
- The revised prices of 543 brands and packs include reductions of up to 93% in some cases.
- Several expensive patented medicines, including Keytruda, remain unchanged.
- Experts say continuous price monitoring and better regulation of manufacturer-level prices are also necessary.
Cancer Drug Mark-ups Reach 700% Despite Earlier Price Controls
The latest findings highlight a weakness in India’s approach to controlling cancer medicine prices.
In February 2019, the NPPA introduced a trade-margin restriction on 42 non-scheduled anti-cancer medicines. The measure capped trade margins at 30% of the maximum retail price (MRP), with the aim of reducing excessive mark-ups charged through the distribution chain.
The intervention initially resulted in significant price reductions across hundreds of medicine brands.
However, a review of the medicines included in the earlier exercise found that many had again recorded substantial mark-ups by 2026.
According to reporting by The Times of India on October 31, 2026, the mark-ups on medicines included in the 2019 list ranged from around 43% to more than 700% in the latest analysis.
The findings were highlighted by the All-India Drug Action Network (AIDAN), a patient-rights and access-to-medicines advocacy organisation.
The organisation argued that a one-time reduction in maximum retail prices does not guarantee that excessive margins will remain controlled over the longer term.
What Happened to Cancer Drug Prices After the 2019 NPPA Order?
The 2019 intervention produced substantial reductions in the prices of several anti-cancer medicines.
However, the latest comparison indicates that some prices subsequently increased, weakening the long-term impact of the original measure.
Example: Pemetrexed price changes
Pemetrexed is a chemotherapy medicine used to treat certain cancers, including lung cancer and mesothelioma.
| Price comparison | Amount |
|---|---|
| Price before 2019 intervention | ₹7,000 |
| Price after 2019 intervention | ₹800 |
| Price before latest 2026 revision | ₹1,095 |
| Price after latest revision | ₹297 |
The example demonstrates two things.
First, the 2019 intervention initially delivered a substantial reduction. Second, the price later increased from ₹800 to ₹1,095 before the latest revision brought it down again.
This is why patient advocates are calling for continuous monitoring rather than relying only on occasional price reductions.
Why Are Cancer Medicines So Expensive in India?
Cancer medicine prices are influenced by several factors, including manufacturing costs, research and development expenditure, patents, competition, distribution margins and the pricing decisions of pharmaceutical companies.
However, the latest NPPA analysis has drawn particular attention to the difference between the price charged by manufacturers and the final price paid by patients.
A medicine can pass through several stages before reaching a patient:
- Manufacturer produces the medicine and sets its selling price.
- Stockists and distributors purchase and supply the product.
- Retail pharmacies or hospitals procure the medicine.
- The final price is charged to the patient.
Each stage can influence the final amount paid.
When distribution margins become excessive, the difference between the manufacturer’s price and the retail price can become very large.
The government’s trade-margin rationalisation policy is designed to address this part of the pricing problem.
However, it does not automatically control every component of the manufacturer’s original price.
Understanding the Difference Between Trade Margin and Mark-up
One important distinction in the cancer-drug pricing debate is the difference between a trade margin and a mark-up.
These terms are related but are calculated differently.
- Trade margin: The distributor’s or retailer’s profit as a percentage of the final selling price.
- Mark-up: The amount added to the purchase price, expressed as a percentage of the original cost.
For example, if a distributor purchases a medicine for ₹100 and sells it for ₹200, the mark-up is 100%.
However, the trade margin is 50% because the distributor earns ₹100 on a final selling price of ₹200.
This distinction matters because a 30% trade-margin cap is equivalent to a maximum mark-up of approximately 42.86% on the purchase price.
Therefore, when reports describe mark-ups exceeding 700%, they are not necessarily saying that every cancer medicine is being sold at seven times its manufacturing cost. The calculation depends on the price base used in the supply chain.
Government Extends Price Intervention to 137 Cancer Drugs
The government has introduced a fresh intervention to address excessive trade margins.
On October 17, 2026, the Department of Pharmaceuticals announced that the NPPA would rationalise trade margins on 137 identified non-scheduled anti-cancer medicines.
The policy applies a 30% trade-margin limit under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
The government expects the intervention to reduce the maximum retail prices of affected medicines by up to 70%, depending on their existing price structures.
The list includes medicines used in chemotherapy, immunotherapy and targeted cancer treatment.
Some of the important medicines covered include:
| Medicine | Therapeutic use |
|---|---|
| Pembrolizumab | Immunotherapy used in several cancer types |
| Durvalumab | Immunotherapy used in certain cancers |
| Osimertinib | Targeted treatment for certain lung cancers |
| Denosumab | Used in certain cancer-related bone conditions |
| Pegfilgrastim | Helps prevent neutropenia during cancer treatment |
| Bevacizumab | Used in certain colorectal, ovarian and cervical cancers |
The revised prices are scheduled to become effective on November 9, 2026.
Manufacturers, distributors, retailers and hospitals will be required to follow the revised prices and display updated price lists.
NPPA Revises Prices of 543 Cancer Drug Brands
The latest government intervention has already resulted in changes to the maximum retail prices of hundreds of cancer medicine brands and packs.
According to a Business Standard report published on October 28, the NPPA revised prices for 543 brands and pack sizes, with reductions reaching up to 93% in certain cases.
However, the reductions are not uniform.
Some generic and biosimilar medicines recorded substantial price cuts, while several expensive originator brands remained unchanged.
Examples of cancer drug price reductions
| Medicine or brand | Previous MRP | Revised MRP | Approximate reduction |
|---|---|---|---|
| Palbopro 125 mg, 21 capsules | ₹40,421 | ₹2,720 | 93.3% |
| Samtepa 100 mg vial | ₹80,072 | ₹7,150 | 91.1% |
These examples show how restricting excessive trade margins can produce substantial savings when a medicine’s existing retail price includes large supply-chain mark-ups.
However, the impact varies by brand, formulation and manufacturer.
Why Are Some Expensive Cancer Drugs Still Unchanged?
One of the biggest concerns surrounding the latest price revision is that several high-cost cancer medicines have not received meaningful price reductions.
For example, Keytruda, an immunotherapy medicine containing pembrolizumab, remains listed at approximately ₹2.16 lakh for a 100 mg vial in the revised comparison reported by NDTV.
Other originator medicines, including Tagrisso, Tecentriq and Imfinzi, have also remained unchanged in the reported price comparison.
The reason is connected to the way trade-margin controls work.
If a medicine’s final price is already close to the manufacturer’s original selling price, reducing distributor and retailer margins may have limited impact.
This is particularly important for patented medicines with limited competition, where the manufacturer’s starting price can itself be very high.
Consequently, a 30% trade-margin restriction cannot guarantee a 30% reduction in the final price of every cancer medicine.
Experts Demand Continuous Monitoring of Cancer Drug Prices
Patient advocacy groups have argued that the government must monitor medicine prices regularly instead of relying on occasional price interventions.
Malini Aisola of the All-India Drug Action Network has questioned whether one-time reductions can prevent margins from increasing again.
The organisation has also raised concerns about the availability and quality of pricing data across retail pharmacies, hospitals and other distribution channels.
Another issue is the difference between the maximum retail price and the actual amount patients pay.
Hospitals may procure medicines directly, while pharmacies and e-pharmacies may offer different discounts. The same medicine can therefore have different transaction prices depending on where it is purchased.
Experts have also argued that the government should examine manufacturer-level pricing, patent-related barriers and the availability of generic alternatives.
The broader debate is no longer limited to distributor margins. It also concerns how the initial prices of expensive medicines are determined.
What Does This Mean for Cancer Patients?
The latest price revisions could provide meaningful relief to patients who depend on medicines with excessive distribution mark-ups.
However, the financial burden of cancer treatment extends beyond the cost of medicines.
Patients may also need to pay for:
- Surgery and hospitalisation.
- Chemotherapy and immunotherapy administration.
- Radiation therapy.
- Diagnostic tests and scans.
- Follow-up consultations.
- Supportive medicines and treatment-related care.
A reduction in the price of one medicine does not necessarily translate into an equivalent reduction in the overall treatment bill.
Patients and caregivers should check the revised prices of the exact brand and formulation prescribed to them through the NPPA website or the Pharma Sahi Daam application.
They should also consult their oncologist before considering any alternative brand or formulation.
The Bigger Picture
India’s cancer medicine pricing debate highlights the limitations of regulating distribution margins without maintaining continuous oversight of the entire supply chain. The 2019 intervention showed that substantial reductions are possible, but the latest findings suggest that the benefits can weaken when prices and margins are not monitored regularly.
The government’s new exercise covering 137 medicines is a significant expansion of the policy. However, the unchanged prices of some expensive patented treatments demonstrate that affordability requires more than trade-margin controls. Competition, generic availability, manufacturer pricing and patient assistance programmes will also influence how much patients ultimately pay.
Looking Ahead
The revised prices of the 543 brands and packs are expected to take effect from November 9, 2026. The government will need to monitor compliance among manufacturers, distributors, retailers and hospitals to ensure that patients actually receive the announced reductions. Regular updates to the price list will also be important as new medicines and brands enter the market.
The longer-term challenge is to prevent excessive mark-ups from returning and address the high starting prices of medicines with limited competition. Whether the latest intervention delivers lasting affordability will depend on the quality of price monitoring, transparency in the supply chain and the government’s willingness to review the pricing framework over time.
Frequently Asked Questions
1. Why have cancer drug prices in India risen by up to 700%?
An NPPA analysis found trade mark-ups of up to 700% on some non-scheduled cancer medicines. The findings suggest that excessive margins returned in parts of the distribution chain after the 2019 price intervention.
2. What did the NPPA do in 2019?
In February 2019, the NPPA imposed a 30% trade-margin restriction on 42 non-scheduled anti-cancer medicines. The intervention reduced the maximum retail prices of hundreds of brands.
3. What is the latest government decision on cancer drug prices?
The government has extended trade-margin rationalisation to 137 non-scheduled anti-cancer medicines. The NPPA has capped trade margins at 30% under the Drugs (Prices Control) Order, 2013.
4. When will the revised cancer medicine prices take effect?
The revised prices are scheduled to become effective from November 9, 2026.
5. Will all cancer medicines become cheaper?
No. The price reductions depend on the existing price structure and distribution margins of each medicine. Some generic medicines have recorded significant reductions, while several expensive patented medicines remain unchanged.
6. Why is Keytruda still expensive?
Keytruda is a patented immunotherapy medicine with a high manufacturer-level price. Restricting distribution margins does not automatically reduce the price charged by the manufacturer.
7. How can patients check revised cancer medicine prices?
Patients can check updated prices through the NPPA website and the Pharma Sahi Daam application. They should verify the exact brand, strength and formulation.
8. What is the difference between a trade margin and a mark-up?
A trade margin is calculated as a percentage of the final selling price, while a mark-up is calculated as a percentage of the original purchase price. A 30% trade margin corresponds to a mark-up of approximately 42.86%.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
